|
T118066 |
CDK9 inhibitor HH1
|
8019-9719 |
CDK
|
|
CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM. |
|
T16363 |
NVP-2
|
|
Apoptosis
,
CDK
|
|
NVP-2 is an effective and selective ATP-competitive cyclin-dependent kinase 9 (CDK9) probe. NVP-2 induces cell apoptosis. NVP-2 inhibits CDK9/CycT activity (IC50: 0.514 nM). NVP-2 shows inhibitory effcts on CDK1/CycB, CD... |
|
T10096L |
Voruciclib
|
|
CDK
|
|
Voruciclib is an orally active and selective CDK inhibitor (Ki: 0.626 nM-9.1 nM). Voruciclib represses the expression of MCL-1 in multiple models of diffuse large B-cell lymphoma. Voruciclib effectively blocks CDK9, the ... |
|
T14918 |
CDK9-IN-2
|
|
Others
,
CDK
|
|
|
|
T9615 |
CK7
|
|
CDK
|
|
CK7, a Cdk2/9 inhibitor, is instrumental in the synthesis of Nek1 inhibitors BSc5231 and BSc5367. |
|
T5438 |
PROTAC CDK9 Degrader-1
|
|
CDK
|
|
PROTAC CDK9 Degrader-1 is a selective CDK9 degrader. |
|
T9446 |
KB-0742 dihydrochloride
|
|
CDK
|
|
KB-0742 dihydrochloride is a potent, selective and orally inhibitor of CDK9. |
|
T8972 |
FIT-039
|
|
Others
,
DNA/RNA Synthesis
,
CDK
,
HSV
|
|
FIT-039 is a selective and ATP-competitive, orally active inhibitor of CDK9( IC50 : 5.8 μM;CDK9/cyclin T1). FIT-039 inhibits replication of HSV-1 (IC50 of 0.69 μM), HSV-2, human adenovirus, and human CMV. FIT-039 is a pr... |
|
T10746 |
CDK9-IN-8
|
|
CDK
|
|
CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM). |
|
T10742 |
CDK9-IN-10
|
|
CDK
|
|
CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2. |
|
TQ0078 |
CDK-IN-2
|
CDK inhibitor II |
CDK
|
|
CDK-IN-2 (CDK inhibitor II) is a potent and specific CDK9 inhibitor (IC50: <8 nM). |
|
T8484 |
JSH-150
|
|
CDK
|
|
JSH-150 is a highly selective CDK9 inhibitor(IC50 : 1 nM). |
|
T70388L |
(R)-Enitociclib
|
|
CDK
|
|
(R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity. |
|
T10464L |
Atuveciclib Racemate
|
BAY-1143572 Racemate |
CDK
|
|
Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib, which is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM. |
|
T6563 |
LDC000067
|
LDC067 |
Apoptosis
,
CDK
|
|
LDC000067 (LDC067) is a highly specific and selective CDK9 inhibitor with an IC50 value of 44±10 nM. |
|
T60619 |
CDK9-IN-15
|
|
CDK
|
|
CDK9-IN-15 is a potent small molecule CDK9 inhibitor, which can block the phosphorylation of positive transcription elongation factor b (P-TEFb) on the C-terminal region of RNA Poly-II by degradation and inhibition of CD... |
|
T10745 |
CDK9-IN-7
|
|
CDK
|
|
CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM). |
|
T60152 |
AZ5576
|
|
CDK
|
|
AZ5576 is a potent and highly selective CDK9 inhibitor. AZ5576 can be used for the research of Hematological Malignancy [1]. |
|
TQ0053 |
Fadraciclib
|
CYC065 |
CDK
|
|
Fadraciclib (CYC065) is an orally available, second-generation ATP-competitive inhibitor of CDK2/CDK9 kinases (IC50s: 5/26 nM). |
|
T6206 |
PHA-767491
|
CAY10572,PHA767491,PHA 767491 |
cholecystokinin
,
GSK-3
,
CDK
|
|
PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively. |
|
T8796 |
CAN508
|
|
CDK
|
|
CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. It is also a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 μM, respectively.CAN50... |
|
T13467 |
(±)-Enitociclib
|
(±)-BAY-1251152 |
CDK
|
|
(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9. |
|
T6924 |
Riviciclib hydrochloride
|
P276-00 |
Apoptosis
,
CDK
|
|
Riviciclib hydrochloride (P276-00) is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Phase 2/3. |
|
T10436 |
AZD4573
|
|
CDK
|
|
|
|
T14919 |
CDKI-73
|
|
Apoptosis
,
CDK
|
|
CDKI-73 is a potent CDK9 inhibitor (Ki: 4 nM). It shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM).The inhibition of CDK9 induces apoptosis and potentiates the effe... |
|
T2506 |
AZD-5438
|
AZD5438 |
CDK
|
|
AZD-5438 is an effective inhibitor of CDK, for CDK1(IC50=16 nM), CDK2(IC50=6 nM), CDK9(IC50=20 nM). |
|
TQ0060 |
LY2857785
|
|
Apoptosis
,
CDK
|
|
LY2857785 is a type I competitive and reversible ATP kinase inhibitor against CDK7/CDK8/CDK9 (IC50s: 246 nM/16 nM/11 nM). |
|
T5533 |
MC180295
|
(rel)-MC180295 |
CDK
|
|
MC180295 ((rel)-MC180295) is a novel potent, highly selective CDK9 inhibitor (IC50: 5 nM), displays >22-fold selectivity over other CDKs. |
|
T70388 |
(S)-Enitociclib
|
VIP152 |
CDK
|
|
(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins. |
|
T10744 |
SEL120-34A
|
|
CDK
|
|
SEL120-34A is a selective and ATP-competitive inhibitor of CDK8 with IC50s of 4.4 nM, 10.4 nM and 1070 nM for CDK8/CycC, CDK19/CycC and CDK9/cycT. SEL120-34A possesses antitumor activity. |
|
T77810 |
XPW1
|
|
CDK
|
|
XPW1 is a new potent and selective CDK9 inhibitor with antitumour activity that transcriptionally inhibits the DNA repair process in ccRCC cells.XPW1 can be used to study clear cell renal cell carcinoma. |
|
T39752 |
CDK12-IN-2
|
CDK12 inhibitor 2,CDK12-IN-2 |
CDK
|
|
CDK12-IN-2 (CDK12 inhibitor 2) is an effective and selective inhibitor of CDK12 with an IC50 of 52 nM, >100 μM, >10 μM and 16 μM for CDK12, CDK2, CDK7, and CDK9. CDK12-IN-2 can be used in studies about the function of CD... |
|
T6940 |
PHA-767491 hydrochloride
|
CAY10572,PHA-767491,PHA767491 HCl,CAY-10572 hydrochloride |
Apoptosis
,
GSK-3
,
CDK
|
|
PHA-767491 hydrochloride (CAY-10572 hydrochloride) is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM). It has ~20-fold selectivity against GSK3-β and CDK1/2, 50-fold selectivity against CDK5 and MK... |
|
T1912 |
Dinaciclib
|
SCH 727965,PS-095760 |
Apoptosis
,
CDK
|
|
Dinaciclib (SCH 727965) is a CDK inhibitor that selectively inhibits CDK1, CDK2, CDK5, and CDK9 (IC50 score = 3/1/1/4 nM). Dinaciclib has potential antitumor activity and inhibits the incorporation of thoracic glycan (dT... |
|
T23840 |
BUR1
|
BMP upregulator-1,BMP upregulator 1,BUR 1,BUR-1 |
CDK
|
|
BUR1 is a selective BMP upregulator that acts by increasing the expression of Inhibitor of DNA binding 1 and inducing BMP2 and PTGS2 expression. |
|
T2378 |
RGB-286638 free base
|
|
GSK-3
,
MEK
,
JAK
,
CDK
|
|
RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 a... |
|
T22461 |
YKL-5-124
|
|
CDK
|
|
YKL-5-124, a potent, selective and covalent CDK7 inhibitor with an IC50 of 9.7 nM, 1300 nM and 3020 nM for CDK7/Mat1/CycH, CDK2 and CDK9 respectively, displays biochemical and cellular selectivity for CDK7 over CDK12/13... |
|
T10220 |
LSN2839567
|
Abemaciclib metabolite M2 |
CDK
|
|
LSN2839567 (Abemaciclib metabolite M2) is the active metabolite of Abemaciclib, a potent CDK4 and CDK6 inhibitor (IC50s: 1-3 nM) with anticancer activity.LSN2839567 inhibits CDK9.LSN2839567 inhibits cell growth and cell ... |
|
T1778 |
AT7519 Hydrochloride
|
AT7519 HCl,AT 7519 hydrochloride salt |
Apoptosis
,
GSK-3
,
CDK
|
|
AT7519 Hydrochloride (AT7519 HCl) is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9. |
|
T2029 |
Bohemine
|
|
ERK
,
CDK
|
|
Bohemine is a cyclin-dependent kinase inhibitor. |
|
T6205 |
AT7519
|
|
Apoptosis
,
GSK-3
,
CDK
|
|
AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7. |
|
T10898 |
Samuraciclib hydrochloride
|
ICEC0942 hydrochloride,CT7001 hydrochloride |
Apoptosis
,
CDK
|
|
Samuraciclib hydrochloride (ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold h... |
|
T14943 |
CGP60474
|
|
VEGFR
,
CDK
,
PKC
|
|
CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC. CGP60474 is also a highly potent anti-endotoxemic agent and inhibits cyclin-dependent kinase (CDK) potently. |
|
T10741 |
CDK9-IN-1
|
|
CDK
|
|
CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection (IC50: 39 nM for CDK9/CycT1). |
|
T70400 |
CDK9/CycT1-IN-93
|
|
|
|
CDK9/CycT1-IN-93 is a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity. |
|
T23775 |
BAY-958
|
BAY 958 |
|
|
BAY-958 is a potent and selective inhibitor of PTEFb/CDK9. |
|
T10743 |
CDK9-IN-11
|
|
CDK
|
|
CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1]. |
|
T10747 |
CDK9-IN-9
|
|
CDK
|
|
CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM). |
|
T28805 |
SLM6
|
NSC-107517,NSC 107517,Sangivamycin-Like Molecule 6,SLM 6,SLM-6 |
|
|
SLM6, an inhibitor of cyclin-dependent kinase-9 (CDK9), exhibits potent anti-multiple myeloma activity. |
|
T68913 |
CCT068127
|
|
|
|
CCT068127 is a potent CDK2 and CDK9 inhibitor. |
